drugset / Trial / NCT06541730
A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of continuous oral administration of DA-302168S tablets for 28 days in overweight/obese subjects.
Timeline
- Start
- 2024-08-30
- Primary completion
- 2025-01-30
- Completion
- 2025-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-302168S | Small molecule | 15 mg | Oral |